Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Colorectal cancer in 2013

Towards improved drugs, combinations and patient selection

Nature Reviews Clinical Oncology volume 11, pages 79–80 (2014)Cite this article

Subjects

The year 2013 has brought more options for patients with metastatic colorectal cancer (mCRC) with new ways to combine traditional agents, further refinement of predictive molecular for EGFR inhibitors and a new salvage option. Molecular profiling could identify subgroups to further improve treatment selection.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Falcone, A. et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group [abstract]. J. Clin. Oncol. 31 (Suppl.), a3505 (2013).

    Google Scholar 

  2. Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023–1034 (2013).

    Article  CAS  PubMed  Google Scholar 

  3. Schwartzberg, L. et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3631 (2013).

    Google Scholar 

  4. Stintzing, S. et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients [abstract]. Eur. J. Cancer 47, LBA17 (2013).

    Google Scholar 

  5. Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase III trial. Lancet Oncol. 14, 29–37 (2013).

    Article  CAS  PubMed  Google Scholar 

  6. Carrato, A. et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J. Clin. Oncol. 31, 1341–1347 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Schmoll, H. J. et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J. Clin. Oncol. 30, 3588–3595 (2012).

    Article  CAS  PubMed  Google Scholar 

  8. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381, 303–312 (2013).

    Article  CAS  PubMed  Google Scholar 

  9. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619–625 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Oncology-Haematology, Martin Luther University Halle–Wittenberg, Ernst Grube Strasse 40, Halle, 06120, Germany

    Hans-Joachim Schmoll

  2. Department of Oncology, Haematology, Stem Cell Transplantation with the Section Pneumology, Hubertus Wald Tumour Centre, University Cancer Centre Hamburg, Martinistrasse 52, Hamburg, 20246, Germany

    Alexander Stein

Authors
  1. Hans-Joachim Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Joachim Schmoll.

Ethics declarations

Competing interests

H.-J. Schmoll has received honoraria from Amgen, Bayer, Sanofi, Merck Serono, and Roche, and research support from Roche. A. Stein has received honoraria from Amgen, Bayer, Sanofi, Merck Serono, and Roche, and research support from Roche and Sanofi.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmoll, HJ., Stein, A. Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol 11, 79–80 (2014). https://doi.org/10.1038/nrclinonc.2013.254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.254

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing